Prostate Center of Academic Urology receives accreditation from ACR, ASTRO

NewsGuard 100/100 Score

The Prostate Center of Academic Urology has been awarded a three-year term of accreditation in radiation oncology from the American College of Radiology (ACR) and The American Society for Radiation Oncology (ASTRO). The Prostate Center provides radiation therapy for men with cancer or other diseases of the prostate. In 2011, the Prostate Center treated 300 men and provided nearly 12,000 treatments, making it one of the most active centers for prostate cancer treatment in the Delaware Valley.

"We are proud to receive this accreditation," said David J. Ellis, MD, president of Academic Urology, "because it means our Prostate Center provides the highest levels of quality and patient safety." Accreditation is awarded only to facilities meeting specific standards in patient care and treatment, patient safety, personnel qualifications, facility equipment, quality control procedures, and quality assurance programs. "The review process is rigorous and achieving a three-year accreditation is a significant accomplishment and benefit to our patients," Dr. Ellis said.

Source:

Prostate Center of Academic Urology

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lancet Commission predicts sharp increase in global prostate cancer cases